Introduction
The tumour necrosis factor (TNF) receptor superfamily and its ligands are increasingly recognized as key regulators of a plethora of fundamental biological processes, including apoptosis, inflammation, immune regulation and oncogenesis. TNF and its receptors, TNFRI and TNFRII, comprise the prototypic receptor/ ligand system and the most well-studied system. The activation of TNFR1 engages two distinct intracellular pathways: the first promotes cell survival through the rapid transient induction of the transcription factor NFkB and is capable of suppressing a second, proapoptotic pathway that triggers caspase activation (Wajant et al., 2003) . The balance of these pro-and antiapoptotic activities dictates the fate of a cell receiving TNF signals and typifies a regulatory circuit common to a number of TNF receptor family members, including Fas, CD30 and CD40 (Hess and Engelmann, 1996; Grell et al., 1999; Eliopoulos et al., 2000; Fulda and Debatin, 2004; Houston and O'Connell, 2004) . The expression levels of intracellular components of this circuit, such as those of the TNF receptor-associated factor (TRAF) family, the magnitude and duration of the signals received and/or the extent of oligomerization of the receptor may influence the decision between survival and death. Indeed, there is accumulating evidence to suggest that whereas high-dose transient TNF treatment may result in apoptosis, constitutive TNF receptor engagement by physiological levels of TNF is proinflammatory and oncogenic (Anderson et al., 2004) .
Despite the absence of significant homology between the cytoplasmic tails of CD40 and TNFR1, CD40 activation also induces pleiotropic effects on cell growth. Thus, the engagement of CD40 by its ligand, CD40L/ CD154, which is transiently expressed in activated T cells, provides critical survival and proliferative signals in normal resting B lymphocytes engaged in secondary immune responses, promoting their differentiation into immunoglobulin-producing plasma cells (Gordon, 1995) . In contrast, the effects of CD40 ligation on malignant B cells range from proliferation and rescue from apoptosis to growth inhibition and induction of cell death in vitro and in vivo (Costello et al., 1999) . Moreover, CD40L has been detected in certain types of malignant B cells, such as chronic lymphocytic leukaemia, Burkitt lymphoma and non-Hodgkin's lymphoma, where it confers oncogenic effects via the constitutive engagement of the CD40 pathway (Furman et al., 2000; Challa et al., 2002; Pham et al., 2002) . These differential effects of CD40 activation on B-cell growth may reflect differences in CD40 signalling in a cell-type and/or differentiation state-dependent manner.
However, CD40 is not only expressed in B lymphocytes but is also found in a wide range of other cell types, including fibroblasts, cardiomyocytes, endothelial, smooth muscle and neuronal cells, raising the possibility that the CD40 pathway may have a broader contribution to human physiology and disease pathogenesis. Indeed, recent studies have highlighted a role for constitutive CD40 signalling in autoimmune diseases (Mohan et al., 1995; MacDonald et al., 1997; Kyburz et al., 2000) and atherosclerosis (Phipps, 2000) . CD40 is also expressed at low levels in normal human epithelium and this expression is dramatically upregulated in psoriasis, an inflammatory skin disease (Ohta and Hamada, 2004) , in HPV-infected normal cervical epithelium (Hill et al., 2005) and in a variety of carcinomas, including those of the ovary, bladder, oropharynx, cervix and breast Cooke et al., 1999; Tong et al., 2001; Hill et al., 2005) . Interestingly, in certain tumour types, such as soft tissue sarcomas, CD40 overexpression correlates with unfavourable patient prognosis (Ottaiano et al., 2004) . Therefore, it is possible that the CD40 pathway may contribute to the pathogenesis of cancer. In this study, we provide evidence to support a role for constitutive CD40 signalling in epithelial oncogenesis. We demonstrate the presence of CD40 and CD40L in primary human epithelial tumours and show that coexpression of these molecules confers oncogenic effects on epithelial cells in vitro. Moreover, we show that an engineered constitutively active CD40 molecule functions as an oncogene in that its expression in Rat-1 fibroblasts induces their transformation in vitro and oncogenicity in vivo.
Results

CD40 and CD40L are coexpressed in primary human carcinomas
To address the hypothesis that CD40 and its ligand play a role in epithelial oncogenesis, we first examined whether these proteins are coexpressed in primary human epithelial tumours. To this end, immunohistochemical analysis for CD40 and CD40L was performed in 160 biopsies from breast cancer patients. The majority of these specimens (85%) were found to be positive for CD40 (Figure 1a) , consistent with previous reports using a smaller number of tissue biopsies (Hirano et al., 1999; Tong et al., 2001) . Interestingly, most of the breast cancer biopsies evaluated (86.4%) also stained positive for CD40L (Figure 1b (e) RNA was isolated from laser capture microdissected tumour cells from four representative breast cancer biopsies and subjected to RT-PCR using primers specific for CD40, CD40L and, as an amplification control, GAPDH. A total of 45 PCR amplification cycles were performed. The first lane represents cDNA synthesis and PCR reactions without RT (RTÀ), which confirms the absence of DNA contamination 75.7% of the tumours examined coexpressed CD40 and CD40L and only 9.2% were positive for CD40 but negative for its ligand. CD40L was localized at both the plasma membrane and the cytoplasm of tumour cells, indicating the presence of CD40L cytoplasmic pools (Figure 1b) . Cytoplasmic CD40L, which is readily released as a soluble molecule, has been previously described in primary B cells (Wykes et al., 1998) . Accumulation of cytoplasmic pools of other ligands of the TNF family, such as FasL (CD95L) and TRAIL, has also been reported in various cell types (Kiener et al., 1997; Martinez-Lorenzo et al., 1998) . Semiquantitation of CD40L expression was performed on the basis of the intensity of staining. Thus, 8.2% of the biopsies were graded as expressing high levels of CD40L, 40.4% were of intermediate intensity and 37.8% showed weak staining. The presence of CD40L was not restricted to breast tumours, as it was also detected in a number of primary colorectal carcinomas (AJ Baxendale and AG Eliopoulos, unpublished observations). However, nonmalignant mammary epithelium stained negative for CD40L expression ( Figure 1c ). To confirm that the protein detected by the immunohistochemical procedure was indeed CD40L, tumour cells were isolated from representative breast cancer biopsies using laser capture microdissection (LCM). A typical microdissected tumour area is shown in Figure 1d . RNA extracted from isolated tumour cells was used for reverse transcriptase (RT)-PCR for the detection of CD40, CD40L and, as a control, the housekeeping gene GAPDH. The PCR products were resolved in ethidium bromide-stained agarose gels and either photographed (CD40 and GAPDH) or transferred to nitrocellulose membrane (CD40L) and hybridized with a radiolabelled CD40L-specific oligo probe to confirm specificity of the CD40L amplified product. The results showed expression of CD40 RNA in all these tumour samples and of CD40L RNA in three of the four specimens analysed (Figure 1e ). The relatively weak signal observed in the PCR reactions may be the result of low amounts and/or quality of RNA isolated from these primary tumour cells and, as a result, the PCR data cannot provide definitive conclusions about the levels of CD40L RNA expressed in breast cancer biopsies. However, these data provide further qualitative evidence that CD40 and CD40L are coexpressed in primary human tumours. Therefore, it is likely that the CD40 pathway is constitutively activated in human epithelial tumours and may contribute to the oncogenic phenotype of carcinomas.
Constitutive engagement of the CD40 pathway mediates oncogenic effects on the immortalized epithelial cell line SCC12F
Recent studies in Burkitt lymphoma cell lines and primary non-Hodgkin's lymphomas have demonstrated that the constitutive production of CD40L by the malignant cells provides an important signal for autonomous cell growth and oncogenic transformation (Challa et al., 2002; Pham et al., 2002) . On the basis of these published reports and the data described in Figure 1 , we reasoned that the constitutive engagement of the CD40 pathway may also confer oncogenic effects in nonhaemopoietic cells. To address this hypothesis, we generated and expressed a tetracycline (tet)-regulatable CD40L expression vector in SCC12F cells, an immortalized but nontumorigenic human epithelial cell line that naturally expresses CD40 (Eliopoulos et al., 1996) . RT-PCR was performed using RNA isolated from two stable clones (clones 15 and 24) and confirmed expression of CD40L following removal of the tetracycline analogue doxycycline (tet-off system; Figure 2a ). As this inducible system is not always tightly regulated, SCC12F/CD40L clone 24 cells expressed some CD40L also in the presence of doxycycline (Figure 2a ). Immunocytochemistry was performed in SCC12F/CD40L clone 24 cells cultured in the absence of tetracycline to verify the production of full-length protein and to determine the percentage of cells expressing CD40L. As a control, mouse L fibroblasts stably expressing CD40L (L/CD40L; Flores-Romo et al., 1997) were used. The results showed that whereas the SCC12F/neo control line was negative for the expression of CD40L, SCC12F/ CD40L clone 24 and L/CD40L cells stained almost uniformly positive (Figure 2b ). To determine whether the expression of CD40L in the SCC12F transfectants is functional and promotes the constitutive engagement of CD40, we examined the activation status of NF-kB, an established CD40-induced signalling target (Berberich et al., 1994) . To this end, nuclear proteins were isolated from doxycycline-deprived SCC12F/CD40L cell clones and control cultures and subjected to electrophoretic mobility shift assay (EMSA) using a radiolabelled NFkB or a control Sp1 oligo probe. The results confirmed enhanced DNA binding of NF-kB in SCC12F cells that coexpress CD40 and CD40L but not in cells expressing CD40 alone (Figure 2c ).
Low-level constitutive CD40 engagement by endogenously produced CD40L induces sustained proliferation in Burkitt lymphoma and non-Hodgkin's lymphoma cells (Challa et al., 2002; Pham et al., 2002) . We therefore examined whether the coexpression of CD40 and CD40L results in increased epithelial cell growth. This issue was addressed by [ 3 H]-thymidine incorporation assays in SCC12F/CD40L cells and neo controls cultured for 96 h in the presence or absence of doxycycline. Under these experimental conditions, there was a 2.1-fold increase in the proliferation of control SCC12F cells. Interestingly, the growth of CD40L-expressing clones 15 and 24 was found to increase by approximately 4.7-and 7.1-fold, respectively, in the absence of tetracycline (Figure 3a) . Therefore, the coexpression of CD40 and its ligand results in enhanced proliferation in immortalized epithelial cells.
A common characteristic of human tumour cells is their capacity for tissue invasion and metastasis (Hanahan and Weinberg, 2000) , which can be modelled in vitro by transwell assays. To this end, CD40L-transfected and control SCC12F cells were cultured in the absence or presence of doxycycline for 48 h. Single-cell suspensions of these cultures were plated onto transwell filters in 12-well plates and allowed to migrate to the underside of the filters for 24 h. The cells were then fixed and the extent of migration was quantitated, as described in Materials and methods. Collective data from four independent experiments are depicted in Figure 3b . In the presence of doxycycline, there was little difference between control and SCC12F/CD40L clone 15 cells. However, SCC12F/CD40L clone 24 cells migrated to a significant extent, probably as a result of 'leaky' CD40L expression in this clone (see Figure 2a ). This migration was further enhanced when the cells were cultured in the absence of doxycycline to induce the expression of CD40L. Similarly, the transwell migration of SCC12F/CD40L clone 15 but not of neo control cells was significantly increased in the absence of doxycycline ( Figure 3b ). To confirm that the observed invasive properties of SCC12F/CD40L cells were CD40L dependent, doxycycline-depleted clone 24 cell cultures were plated onto transwell filters in the presence of a neutralizing anti-CD40L (anti-CD154) antibody. A representative assay is shown in Figure 3c and collective data from four experiments are depicted in Figure 3d . These experiments showed that inactivation of the constitutive CD40-CD40L interactions by this neutralizing reagent induced a dramatic reduction in transwell migration. Taken together, the preceding data suggest that the constitutive activation of the CD40 pathway mediates oncogenic effects on immortalized epithelial cells in vitro.
A chimeric molecule comprising the transmembrane domain of Epstein-Barr virus-encoded latent membrane protein-1 fused to the cytoplasmic terminus of CD40 functions as a constitutively active CD40 receptor in Rat-1 fibroblasts Rat-1 is an immortalized rodent fibroblast line, which is susceptible to oncogenic transformation. Indeed, Rat-1 cells have been extensively used for the identification and characterization of human oncogenes, including the viral oncogene latent membrane protein-1 (LMP1) following their culture in the absence of Dox and subjected to EMSA using a radiolabelled NF-kB-specific or an SP1 control oligo probe (Wang et al., 1985; He et al., 2000) . This Epstein-Barr virus (EBV)-encoded protein has been shown to mimic many of the functions of the activated CD40 receptor. Thus, like CD40, LMP1 directly binds TRAFs and activates the NF-kB and MAPK pathways (Gires et al., 1997; Eliopoulos and Young, 2001 ). Moreover, expression of LMP1 in the B-cell compartment of CD40 knockout mice corrects many of the defects caused by the absence of CD40 (Uchida et al., 1999) . Unlike CD40, however, LMP1 functions in a ligand-independent manner. This is achieved by the LMP1 transmembrane domains, which promote the constitutive oligomerization of the TRAF-interacting cytoplasmic C-terminus of the protein (Figure 4a ), the domain responsible for the oncogenic transformation of Rat-1 fibroblasts (He et al., 2000) . We have taken advantage of this property of LMP1 and constructed a chimeric molecule comprising the transmembrane domains of LMP1 fused to the cytoplasmic terminus of CD40 (LMP:CD40; Figure 4a ). We and others have previously shown that transient expression of this molecule mediates the activation of CD40 signalling pathways in a CD40 ligand-independent manner (Gires et al., 1997; Eliopoulos and Young, 1998) . LMP:CD40, LMP1 and wild-type CD40 were transfected in Rat-1 fibroblasts and stable clones were obtained. Immunoblot analysis using antibodies against the C-terminus of CD40 or the C-terminus of LMP1 confirmed expression of the transfected genes ( Figure 4b ). To determine whether the expression of LMP:CD40 in these stable clones is functional and promotes the constitutive engagement of CD40, we examined the activation status of NF-kB by EMSAs using a radiolabelled NF-kB oligo probe. The results confirmed enhanced DNA binding of NF-kB in Rat-1/ LMP:CD40 clone 13 cells compared to cells expressing CD40 alone (Figure 4c) . Moreover, the NF-kB activity of the LMP:CD40 clone was similar to that of LMP1-expressing clone 5. Similar levels of activation of JNK and ERK MAPK signalling pathways were also observed in these clones (data not shown). Therefore, stable expression of LMP:CD40 in Rat-1 fibroblasts confers the constitutive engagement of CD40 signalling in a ligand-independent manner. Given the ability of LMP1 to transform rodent fibroblasts and the effects of constitutive CD40 engagement on epithelial cell phenotype described in Figure 3 , we asked whether the constitutive activation of the CD40 pathway by the LMP:CD40 chimaera promotes the oncogenic transformation of Rat-1 cells. To this end, the morphology of Rat-1/LMP:CD40 clone 13 and Rat-1/LMP1 clone 5 cells and their capacity for anchorageindependent growth were examined. These clones were selected for analysis as they showed similar levels of NFkB and MAPK signal activation (Figure 4c and data not shown).
Compared to neo control and CD40-transfected cultures, the LMP:CD40-expressing cells were thinner and elongated, similar to the LMP1 transfectants (Figure 5a ). While control cells remained attached to the plastic surface of the dish, Rat-1/LMP:CD40 fibroblasts detached to a significant extent and reached near-confluency only after prolonged periods of culture. As a consequence of this alteration, we were unable to assess with accuracy the proliferation rate and the migratory capacity of the LMP/CD40-expressing Rat-1 cells. However, we determined their ability for anchorage-independent growth in soft agar. Unlike CD40-expressing or neo control fibroblasts, Rat-1/LMP:CD40 clone 13 cells grew as progressively enlarging foci, which were macroscopically visible by 14 days of culture ( Figure 5b) . As a control, LMP1-transfected Rat-1 fibroblasts were also capable of anchorage-independent growth (Figure 5b ). Quantitation of these phenomena was performed and showed that the efficiency of foci formation by the stable expression of LMP:CD40 was similar to that of the EBV transforming gene LMP1 (Figure 5c ).
To determine whether the in vitro-transformed phenotype of LMP:CD40-expressing Rat-1 fibroblasts translates to oncogenicity in vivo, Rat-1/LMP:CD40 clone 13 and, as a positive control, Rat-1/LMP1 clone 5 cells were inoculated subcutaneously in athymic nude mice. Progressively enlarging LMP:CD40 tumours were formed at the site of inoculation, which by 4 weeks were 56-1100 mm 3 in size. The inoculated LMP1-expressing cells, but not Rat-1 neo control fibroblasts, also formed tumours, which were 49-350 mm 3 in size. While there was a tendency for the LMP:CD40-expressing Rat-1 cells to form somewhat larger tumours than the LMP1 transfectants, this difference was not statistically significant. Haematoxylin and eosin (H&E) staining was performed in paraffin-embedded sections of representative tumours. This analysis demonstrated histological characteristics of a fibrosarcoma for both LMP:CD40 and LMP1 tumours, with the LMP:CD40 tumours showing a slightly higher number of mitotic cells (Figure 5d ). RT-PCR was performed on RNA isolated from these tumours and confirmed expression of LMP:CD40 and LMP1 in vivo (Figure 5e ). Taken together, the preceding data demonstrate that the constitutive engagement of CD40 driven by the transmembrane domains of LMP1 delivers oncogenic signals in fibroblasts.
Transient expression of LMP:CD40 induces anchorageindependent growth in an NF-kB-dependent manner
To confirm that the observed ability of LMP:CD40 to transform Rat-1 fibroblasts is not the result of clonal selection, we utilized transient transfection assays. In parallel, we examined the possibility that the activation of NF-kB contributes to the transforming effects of LMP:CD40. The rationale behind this hypothesis has been provided by previous studies demonstrating an important role for the NF-kB pathway in cellular transformation induced by a number of oncogenes (Rayet and Gelinas, 1999) , including LMP1 (He et al., 2000) . To address this hypothesis, Rat-1 cells were transiently transfected with LMP:CD40 in the presence or absence of a transdominant HA-tagged IkBa mutant -Ala double mutation, which prevents phosphorylation and degradation of IkBa, thereby rendering it a constitutively active inhibitor of NF-kB (Wang et al., 1996) . Indeed, M-IkBa dramatically suppressed the effects of LMP:CD40 on NF-kB transactivation, as determined by luciferase reporter assays (Figure 6a ). Parallel cultures were plated in soft agar and anchorage-independent growth was monitored. By 14 days of culture, the LMP:CD40 but not the vector control transfectants formed colonies in soft agar (Figure 6b) , thus confirming the transforming capacity of constitutive CD40 signalling observed in the stable LMP:CD40 clone 13. Transfection of the LMP1 transmembrane domains alone had no effect on foci formation (data not shown; He et al., 2000) . Interestingly, coexpression of M-IkBa inhibited LMP:CD40-induced colony formation by more than 80% (Figure 6b) .
The ability of M-IkBa to suppress the LMP:CD40-induced transformation could, theoretically, be the result of nonspecific antiproliferative or toxic effects of M-IkBa on the cells. To address this possibility, Rat-1 fibroblasts were transiently transfected with the polyoma virus middle T antigen, which does not require NFkB to mediate its potent oncogenic effects (reviewed by Dilworth, 2002) , in the presence or absence of M-IkBa. The results of this analysis showed that M-IkBa does not affect the ability of middle T to promote the in vitro transformation of Rat-1 fibroblasts (Figure 6c) . We conclude that the transforming effects of constitutive CD40 on fibroblasts are largely mediated by the aberrant activation of the NF-kB pathway.
Discussion
CD40, a TNF receptor family member, is expressed in a variety of cell types, including B lymphocytes, macrophages, fibroblasts, endothelial, epithelial and neuronal cells and this widespread expression is likely to account for its central role in normal physiology and disease pathogenesis. Data presented in this study suggest that the CD40 pathway may also contribute to tumour growth. Thus, our immunohistochemical analysis has demonstrated coexpression of CD40 and CD40L in primary human tumour biopsies, an observation that supports the operation of a constitutively active CD40 receptor in vivo (Figure 1 ). Moreover, we have shown that coexpression of CD40 and CD40L in the immortalized epithelial cell line SCC12F promotes a number of oncogenic alterations, such as increased proliferation, motility and invasion in vitro (Figure 3) . Interestingly, transient stimulation of parental SCC12F cells with recombinant soluble CD40L failed to induce any of these phenotypic changes (data not shown). Therefore, the ability of CD40 to mediate oncogenic effects requires its constitutive engagement. While the coexpression of CD40 and CD40L increased the proliferation, motility and invasion of SCC12F cells, it failed to promote a fully transformed phenotype, as demonstrated by the inability of CD40L-expressing SCC12F cells to grow in soft agar under conditions of anchorage independence (data not shown). This observation does not eliminate a role for the CD40 pathway in epithelial oncogenesis. Indeed, previous work has established that whereas rodent cells require at least two introduced genetic changes before they acquire tumorigenic competence, their human counterparts are more difficult to transform (Hahn et al., 1999) . Consistent with this model of oncogenesis, we have found that the constitutive activation of the CD40 pathway in Rat-1 cells, an immortalized rodent fibroblast cell line, induced dramatic changes in cell morphology and promoted anchorage-independent growth and tumour formation in nude mice (Figures 5  and 6 ). These observations are reminiscent of the transforming properties of the viral oncogene LMP1 in the same cell line (Wang et al., 1985; He et al., 2000) and further support the notion that the constitutive engagement of CD40 confers oncogenic effects.
Transgenic mice expressing CD40L under the control of the epithelial-specific keratin-14 promoter die within 3-5 months after birth as a result of exaggerated chronic skin inflammation (Mehling et al., 2001) . This precludes analysis of the potential effects of constitutive CD40 activation on epithelial carcinogenesis in vivo. However, given the established link between chronic inflammation and cancer (reviewed by Ohshima and Bartsch, 1994; O'Byrne and Dalgleish, 2001) , it is possible that the constitutive engagement of the CD40 pathway predisposes epithelial tissue to malignant conversion in vivo. A role for CD40 in inflammation is highlighted by the observation that CD40 engagement induces the synthesis of the proinflammatory cyclooxygenase-2 (COX-2)/prostaglandin E2 system in lung fibroblasts and disruption of the constitutive CD40-CD40L pathway reduces lung inflammation and fibrosis (Adawi et al., 1998; Zhang et al., 1998) . Similarly, COX-2 inhibitors confer therapeutic benefits for the treatment of lung cancer (reviewed by Liao and Milas, 2004) . A recent report has demonstrated that NF-kB is a critical link between inflammation and cancer, promoting the conversion of chronic inflammatory liver disease to hepatocellular carcinoma in a mouse model (Pikarsky et al., 2004) . It is therefore possible that activated NFkB induced by the constitutive engagement of CD40 confers both inflammatory and oncogenic properties in vivo. Our in vitro findings support a role for NF-kB in oncogenic transformation by CD40, inasmuch as inhibition of NF-kB by a transdominant IkBa suppresses anchorage-independent growth of LMP:CD40-transfected Rat-1 cells (Figure 6 ). At first, the oncogenic functions of CD40 ligation appear to be at odds with the previously proposed therapeutic effects of CD40L in haemopoietic and epithelial tumours (Vonderheide et al., 2001; Eliopoulos and Young, 2004) . Indeed, we and others have previously demonstrated that treatment of malignant cells with high doses anti-CD40 mAb or recombinant soluble CD40L results in growth inhibition and/or apoptosis in vitro and in vivo (Funakoshi et al., 1994; Eliopoulos et al., 1996 Eliopoulos et al., , 2000 Hess and Engelmann, 1996; Baker et al., 1998; Tutt et al., 1998; Grell et al., 1999; Henriquez et al., 1999; Ghamande et al., 2001) . However, there is accumulating evidence to suggest that the level and duration of CD40 engagement may dictate the balance between stimulation and suppression of tumour cell growth. Thus, whereas treatment of L3055 Burkitt lymphoma cells with high concentrations of CD40L promotes substantial growth arrest, low-level engagement can favour proliferation and survival in the same cell line (Challa et al., 2002) . Similarly, neutralization of the low-level constitutive production of CD40L in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia cells inhibits their growth and induces apoptosis (Furman et al., 2000; Pham et al., 2002) . The seemingly contradictory effects of CD40L on tumour growth are reminiscent of other TNF family members, including TNF itself. High-dose TNF treatment promotes apoptosis in carcinoma (Micheau and Tschopp, 2003) and mature T cells (Zheng et al., 1995) in vitro and has anticancer properties in vivo (Eggermont et al., 2003) . However, constitutive TNF receptor engagement by physiological levels of TNF is proinflammatory and oncogenic (Anderson et al., 2004) . The latter is exemplified by the therapeutic impact of anti-TNF agents on haemopoietic malignancies in which TNF is constitutively produced (Anderson et al., 2004) and by studies showing that TNF knockout mice are resistant to chemical-induced skin carcinogenesis (Moore et al., 1999) . It is also of relevance that the EBV-encoded LMP1 appears to function, at least in part, as a constitutive CD40. The oncogenic properties of this viral protein are well established and include the transformation of mouse fibroblasts, increased epithelial cell motility and invasion, B-cell lymphomagenesis and, like CD40L, an inflammatory, psoriatic-like skin in transgenic mice (reviewed by Eliopoulos and Young, 2001) . Intriguingly, however, the overexpression of LMP1 may also result in growth inhibition and apoptosis in lymphoid and epithelial cell lines (Hammerschmidt et al., 1989; Eliopoulos et al., 1996; Floettmann et al., 1996) . The differential promotion of oncogenic and antitumour effects by low versus high CD40, TNF and LMP1 engagement may relate to the expression levels of intracellular signalling components, such as TRAFs, and/or the extent of their recruitment to the activated receptor. In this regard, it is of interest that high-level transient CD40 engagement induces degradation of TRAF2 and the subsequent impairment of CD40 signal transduction while constitutive signalling by LMP1 does not affect TRAF2 expression (Brown et al., 2001) .
Recent studies have characterized an autonomous programme of sustained proliferation and survival induced by the coexpression of CD40 and its ligand in haemopoietic malignancies, such as non-Hodgkin's lymphoma (Pham et al., 2002) , Burkitt lymphoma (Challa et al., 2002) and chronic lymphocytic leukaemia (Furman et al., 2000) . The findings presented in this manuscript, coupled with these published reports, suggest a generalized influence of the constitutive activation of the CD40 pathway in cell transformation and neoplastic growth. It remains to be seen whether disruption of this pathway may have beneficial effects for the treatment of epithelial malignancies where CD40 ligand is expressed.
Materials and methods
Cell lines, plasmids and reporter assays
Rat-1 cells were cultured in DME/HEPES supplemented with 10% FCS and 2 mM glutamine. SCC12F cells were cultured in DME/HEPES supplemented with 5% FCS, 2 mM glutamine and 400 ng/ml hydrocortisone. Tetracycline-regulated CD40L SCC12F clones were generated using the plasmids pJEF3 and pJEF4 ; kindly provided by Professor Martin Rowe, University of Cardiff, UK). The CD40L cDNA was cloned into pJEF4 and the resultant plasmid was transfected into SCC12F cells expressing the tet transactivator, pJEF3, by electroporation. Briefly, 2 Â 10 6 cells were resuspended in media in a final volume of 400 ml and transferred to an electroporation cuvette (Biorad) together with 10 mg of pJEF4-CD40L plasmid DNA. Cells were then pulsed at 1050 mF/260 V, resuspended in media and replated on a layer of gamma-irradiated Swiss-3T3 cells. Cells were selected for hygromycin (200 mg/ml) and geneticin sulphate (400 mg/ml) resistance. Colonies were picked, expanded and screened. Throughout the selection process, the 'feeder' layer of gammairradiated Swiss-3T3 cells and media were refreshed twice a week. The construction of the CD40 and the LMP:CD40 chimaera plasmids has been previously described . Rat-1 cells were transfected using Lipofectamine Plus s (Gibco) according to the manufacturer's instructions. NF-kB reporter plasmids and assays have been previously described (Baker et al., 1998; Eliopoulos and Young, 1998; Eliopoulos et al., 2003) .
Immunohistochemistry and immunoblotting
The immunohistochemical analysis of CD40 expression in primary tumour biopsies was performed as previously described (Hill et al., 2005) . A similar methodology was used for the detection of CD40L expression using a rabbit polyclonal anti-CD40L antibody from Santa-Cruz Biotechnology at 1 : 50 dilution. Immunoblotting was performed as previously described (Baker et al., 1998; Eliopoulos and Young, 1998; Eliopoulos et al., 2003; Hill et al., 2005) 
Transwell assay
Cells were cultured for at least 1 week in the presence or absence of 1 mg/ml doxycycline. Prior to the experiment, cells were replated and 24 h later cells were washed and cultured in DME/HEPES supplemented with 0.5% BSA. During this time cells continued to be cultured7doxycycline as necessary and, at this point, cells were also preincubated with 1 mg/ml anti-CD154 (Ancell). After 24 h cells were washed twice with PBS and gently detached from the dish using a dilute trypsin : ED-TA solution (1 : 100). Cells were pelleted and resuspended in DME/HEPES supplemented with 0.5% BSA and counted. A total of 5 Â 10 4 cells in a final volume of 100 ml were added to transwell inserts (precoated with 10 mg/ml fibronectin (Sigma)) in triplicate for each condition of treatment that is, in the presence of doxycycline, in the absence of doxycycline and in the absence of doxycycline but in the presence of anti-CD154. Transwell inserts were then partially submerged in DME/ HEPES supplemented with 0.5% BSA in 24-well plates and incubated for 24 h. The transwell insert membranes were then fixed in 30% methanol and stained with 1% crystal violet. The membranes were then excised and incubated in 100 ml of 30% acetic acid to dissolve the crystal violet and processed for photometric analysis at 595 nm.
Preparation of nuclear extracts and electrophoretic mobility shift assays
The preparation of nuclear extracts and EMSAs were performed as previously described .
Laser capture microdissection and reverse transcriptase-PCR
The methods for LCM, cDNA synthesis and CD40L PCR have been previously described (Baker et al., 1998; Eliopoulos and Young, 1998; Eliopoulos et al., 2003) . The primers used to amplify LMP1 and LMP:CD40 from mouse tumour RNA were 5 0 -GCG-ACT-CTG-CTG-GAA-ATG-AT-3 0 (LMP1 forward primer), 5 0 -GAC-ATG-GTA-ATG-CCT-AGA-AG-3 0 (LMP1 reverse primer), 5 0 -GAT-CTC-CTT-TGG-CTC-CTC-CTG-3 0 (LMP:CD40 forward primer) and 5 0 -TCA-CTG-TCT-CTC-CTG-CAC-TGA-3 0 (LMP:CD40 reverse primer). The conditions for the LMP1 PCR were 941C for 30 s, 521C for 45 s and 721C for 50 s (28 cycles) and for the LMP:CD40 PCR were 941C for 30 s, 551C for 45 s and 721C for 40 s (35 cycles).
Soft agar focus formation and nude mice tumorigenicity assays
Rat-1 transfectants (5 Â 10 4 cells/well) were seeded in soft agar on six-well plates and the number of foci was recorded 2 weeks later. For in vivo tumorigenicity assays, Rat-1 transfectants (5 Â 10 6 cells/mouse) were inoculated subcutaneously in 4-week-old athymic mice (four mice per transfectant) in 100 ml serum-free DMEM and tumour formation was monitored. The size of the formed tumours was measured on week 4.
